0.578  0.034 (6.17%)		10-24 14:57
Open: 0.547 High: 0.6244 Volume: 501,798		Pre. Close: 0.5444 Low: 0.5467 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	1.01	1-year :	1.27
Resists	First :	0.86	Second :	1.09
Pivot price	0.67
Supports	First :	0.5	Second :	0.42
MAs	MA(5) :	0.58	MA(20) :	0.68
	MA(100) :	1.15	MA(250) :	1.91
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	7.3	D(3) :	5.4
RSI	RSI(14): 34.6
52-week	High :	4.33	Low :	0.31

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AZTR ] has closed above bottom band by 18.1%. Bollinger Bands are 9.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.55 - 0.55	0.55 - 0.56
Low:	0.5 - 0.5	0.5 - 0.5
Close:	0.54 - 0.54	0.54 - 0.55

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Mon, 20 Oct 2025
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris - Seeking Alpha

Mon, 20 Oct 2025
TEWL reduced (p - Stock Titan

Wed, 15 Oct 2025
Phase 1b ATR-12: Azitra's engineered S. epidermidis therapy discussed at Maxim Growth Summit Oct 22-23 - Stock Titan

Wed, 15 Oct 2025
Azitra to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit - Sahm

Fri, 03 Oct 2025
Azitra Inc Faces NYSE Compliance Deadline Notice - TipRanks

Wed, 24 Sep 2025
Azitra (AZTR) Sees Significant Price Target Adjustment by Maxim Group | AZTR Stock News - GuruFocus

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	5 (M)
Shares Float	4 (M)
Held by Insiders	0.5 (%)
Held by Institutions	3.4 (%)
Shares Short	93 (K)
Shares Short P.Month	169 (K)

EPS	26.96
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.82
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-180.8 %
Return on Equity (ttm)	-473.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.08
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	0.02
PEG Ratio	0
Price to Book value	0.69
Price to Sales	0
Price to Cash Flow	-0.29

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.